A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease

StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 8 months later Jan 2028 → Oct 2028
Enrollment reduced 29% 127 → 90 participants
See other at-risk trials from Eli Lilly

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Jan 2028 to Oct 2028
    • Enrollment reduced: 127 → 90 participants
    • Eligibility criteria expanded, about 34 words
    • Study description expanded, about 2 words
  2. Site details revised at 10 of 14 sitesv17
  3. Eligibility criteria expanded, about 50 words
    • Site contacts updated at 1 of 14 sites
    v16
  4. Site details revised at 1 of 14 sitesv15
  5. Re-verified, no change to tracked fieldsv14
Show 12 earlier versionsHide 12 earlier versions
  1. Study sites: 13 to 14v13
  2. Site details revised at 1 of 13 sitesv12
  3. Site contacts updated at 1 of 13 sitesv11
  4. Study sites: 14 to 13v10
  5. Study sites: 13 to 14v9
  6. Eligibility criteria expanded, about 36 wordsv8
  7. Secondary endpoints: 4 to 6v7
  8. Site contacts updated at 1 of 13 sitesv6
  9. Primary endpoints revised (4)v5 Show 4 more changesShow less
    • Primary and study completion dates: Nov 2027 to Jan 2028
    • Eligibility criteria revised
    • Secondary endpoints revised (4)
    • Study sites revised (13)
  10. Study sites: 2 to 13v4
  11. Re-verified, no change to tracked fieldsv3
  12. Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: May 2028 to Nov 2027
    • Start date changed from estimate of Feb 2025 to Feb 18, 2025
    • Site details revised at 2 of 2 sites
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
363 trials monitored
See 16 trials at risk
Parkinson's Disease
1,462 trials monitored
See 71 trials at risk
The purpose of this study is to generate evidence of the safety, tolerability, and pharmacokinetics/pharmacodynamics of IV LY4006896 compared with placebo in healthy participants and participants with Parkinson's disease.
Trial Details
NCT Number NCT06809400
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Parkinson Disease
Related terms Parkinson Disease
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov